Delivery Order SPE2DB22D1202-SPE2DB25FVMQ1
- Not listed
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,957.76 to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This firm fixed-price delivery order represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a $9,257.14 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL. This non-competitive, competitively awarded contract is structured as a firm fixed price delivery order with a completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL pen injections, valued at $46,099.45. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of June 23, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL prefilled pens, with a ceiling value of $1,205.75. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by June 20, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a discrete...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL formulation, valued at $6,797.70 with a firm fixed price structure. Awarded on September 15, 2025, this non-set-aside delivery order is scheduled for completion by September 16, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of HUMIRA (adalimumab) pen injections at 40 mg/0.4 mL. This firm fixed-price delivery order, valued at $27,237.04, represents a non-competitive award issued under an existing indefinite delivery contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of September 15, 2025. This...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVMQ1Delivery Order
The Defense Logistics Agency awarded a $6,405.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 ml dosage. This is a non-set-aside, competitively awarded contract with a completion date of September 29, 2025, and performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal contracting relationship with the Defense Logistics Agency Medical Supply Chain. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical prime vendor for federal military medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 9/26/25 |